| Project/Area Number |
23500531
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biological material science
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAWAGUCHI Kazunori 藤田保健衛生大学, 医療科学部, 講師 (00508468)
NAKAI Shigeru 藤田保健衛生大学, 医療科学部, 教授 (20345896)
ITO Shinji 藤田保健衛生大学, 医学部, 准教授 (40572079)
KATO Masao 藤田保健衛生大学, 医学研究科, 研究員 (50599537)
|
|---|
| Research Collaborator |
SAKAI Kazuyoshi 藤田保健衛生大学, 医療科学部, 准教授 (90215583)
ITO Kengo 国立長寿医療研究センター, 認知症先進医療開発センター脳機能画像診断開発部 (70184653)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | アルツハイマー病 / アミロイドβ / 治療機器 / 血液透析 / 脳病理 / 認知機能 / アフェレシス / 血液浄化 / アミロイドベータ / Aβ / 人工透析 / 脳変化 / アミロイドβ蛋白 / Aβ除去 |
|---|
| Research Abstract |
To create therapeutic systems for Alzheimer's Disease by removal of blood Abeta, the followings were investigated regarding hemodialysis which effectively removes blood Abeta; 1) Abeta depositions as senile plaques in the postmortem brains of hemodialysis patients were significantly less than those of patients without dialysis. 2) The concentrations of plasma Abeta increased along with the decline of renal functions. Moreover, the renal failure patients without hemodialysis and with poorer renal functions showed lower cognitive functions. 3) Along with the initiation of hemodialysis of 5 renal failure patients (64.0+-12.6 y.o.), the concentration of blood Abeta1-40, Abeta1-42, Abeta-oligomers were decreased and the cognitive functions were improved to or kept in full scores.
These results indicates that the blood Abeta reduction systems is worth investigating further as therapeutic systems for Alzheimer's Disease.
|
